CYNO Cynosure - Class A (MM)

Approval Supports Treatment of a Variety of Pigmented Lesions WESTFORD, Mass., March 30 /PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced it has received US Food and Drug Administration clearance for its pulse dye laser (PDL) for the treatment of pigmented lesions, which include freckles, solar lentigines (also known as sun spots or age spots), cafe au lait birthmarks, and other skin lesions such as scars and warts. This new FDA clearance is in addition to the approval that Cynosure had previously obtained for the PDL for treatment of vascular lesions, which include port wine stains, spider veins and the blush of rosacea. Cynosure's 585 nm wavelength PDL is offered in the Cynergy(TM) laser workstation, which includes the PDL along with a high-powered 1064 nm wavelength Nd:YAG laser. "This new FDA clearance opens potential new revenue opportunities for Cynosure," stated CEO Michael R. Davin. "Millions of people are affected by pigmented lesions and other skin irregularities in addition to vascular lesions. U.S. practitioners can now leverage our Cynergy product to treat patients with these types of skin conditions. From a sales perspective, this FDA clearance increases treatment applications of our pulse dye lasers. At the same time, we are continuing to pursue additional clearances, both domestically and abroad, for our diverse line of products." About Cynosure, Inc. Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse-dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosurelaser.com/. Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about potential revenue growth and the company's ability to gain additional regulatory approvals, and other statements containing the words "believes," "anticipates," "plans," "expects," "will," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's Annual Report on Form 10-K, filed with the SEC. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release. Contact: Timothy Baker 800-886-2966 DATASOURCE: Cynosure, Inc. CONTACT: Timothy Baker of Cynosure, Inc., +1-800-886-2966, Web site: http://www.cynosurelaser.com/

Copyright